Safety of statins: Effects on muscle and the liver

Article Type

Article

Changed

Wed, 09/12/2018 - 08:39

Display Headline

Safety of statins: Effects on muscle and the liver

Author(s)

Abu R. Vasudevan, MBBS, MD, MRCP

Yasmin S. Hamirani, MBBS

Peter H. Jones, MD

Article PDF

content_72_990.pdf

Author and Disclosure Information

Abu R. Vasudevan, MBBS, MD, MRCP
Clinical Instructor, Division of Endocrinology and Metabolism, Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Yasmin S. Hamirani, MBBS
Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Peter H. Jones, MD
Associate Professor, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, 6565 Fannin, Suite B160, Mail stop A601, Houston, TX 77030; e-mail [email protected]

Dr. Jones has indicated that he has received grant or research support from the Abbott, AstraZeneca, KOS, and Pfizer corporations.

Issue

Cleveland Clinic Journal of Medicine - 72(11)

Publications

Cleveland Clinic Journal of Medicine

Topics

Page Number

990-993, 996-1001

Sections

Current Drug Therapy

Author(s)

Abu R. Vasudevan, MBBS, MD, MRCP

Yasmin S. Hamirani, MBBS

Peter H. Jones, MD

Author(s)

Abu R. Vasudevan, MBBS, MD, MRCP

Yasmin S. Hamirani, MBBS

Peter H. Jones, MD

Author and Disclosure Information

Abu R. Vasudevan, MBBS, MD, MRCP
Clinical Instructor, Division of Endocrinology and Metabolism, Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Yasmin S. Hamirani, MBBS
Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Peter H. Jones, MD
Associate Professor, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, 6565 Fannin, Suite B160, Mail stop A601, Houston, TX 77030; e-mail [email protected]

Dr. Jones has indicated that he has received grant or research support from the Abbott, AstraZeneca, KOS, and Pfizer corporations.

Author and Disclosure Information

Abu R. Vasudevan, MBBS, MD, MRCP
Clinical Instructor, Division of Endocrinology and Metabolism, Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Yasmin S. Hamirani, MBBS
Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Peter H. Jones, MD
Associate Professor, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, 6565 Fannin, Suite B160, Mail stop A601, Houston, TX 77030; e-mail [email protected]

Dr. Jones has indicated that he has received grant or research support from the Abbott, AstraZeneca, KOS, and Pfizer corporations.

Article PDF

content_72_990.pdf

Article PDF

content_72_990.pdf

Issue

Cleveland Clinic Journal of Medicine - 72(11)

Issue

Cleveland Clinic Journal of Medicine - 72(11)

Page Number

990-993, 996-1001

Page Number